DYADIC INTERNATIONAL INC

Dyadic International announced a collaboration with Scripps Research to develop rapid-response hantavirus antibody and vaccine candidates, including for the Andes virus. This partnership leverages Dyadic's C1 platform for fast, scalable biologic production, building on prior research into Andes, Marburg, and Ebola viruses. The initiative aims to enhance pandemic preparedness by improving the speed, scalability, and cost-effectiveness of biologic manufacturing, with Dyadic also noting growing commercial activity in non-pharmaceutical applications.

Dyadic International announced a collaboration between Dyadic Applied BioSolutions and Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including the Andes virus. This partnership aims to leverage Dyadic's proprietary C1 platform to improve the speed, scalability, flexibility, and cost-effectiveness of biologic manufacturing for public health events. The C1 platform has demonstrated comparable efficacy to traditional mammalian systems in preclinical studies and is already involved in other funded collaborations with organizations like the Gates Foundation and CEPI. Dyadic also continues to focus on commercial opportunities in non-pharmaceutical protein products.

Dyadic International announced that Joe Hazelton, President and Chief Operating Officer, will present at Sidoti's Virtual Investor Conference on May 20, 2026, at 10:00 a.m. ET. Management will also host virtual one-on-one meetings with investors during the conference. The company, operating as Dyadic Applied BioSolutions, is a global biotechnology firm focused on precision-engineered, animal-free proteins and enzymes.

Dyadic International reported a significant increase in total revenue for Q1 2026, rising 182.3% to $1.11 million, while its net loss narrowed to $1.95 million. The company highlighted several key commercial advancements, including the launch of AlbuFree DX recombinant human albumin, an expanded collaboration with Fermbox Bio for recombinant DNase I, and new distribution and development agreements. Dyadic continues to focus on commercializing animal-free recombinant proteins and enzymes through strategic partnerships and direct sales channels.

Dyadic International reported a significant increase in total revenue for Q1 2026, reaching $1.11 million, up 182.2% year-over-year, driven by growth in research, grant, and new license revenue. The company also reduced its net loss to $(1.95) million from $(2.03) million in the prior year. Despite improved operational results, the company's total stockholders' equity turned negative, and it continues to anticipate losses and negative cash flows, relying on existing capital and future financing to meet its operational needs.

Dyadic International reported a significant increase in Q1 2026 total revenue, up 182.3% to $1.11 million, driven by growth in research and development, grant, and license revenue. The company also announced several key commercial milestones, including the launch of AlbuFree DX, an expanded collaboration with Fermbox Bio, and new distribution and development agreements. Despite these advancements, Dyadic recorded a net loss of $1.95 million for the quarter, with cash reserves at $6.6 million.

Dyadic International Inc. announced its 2026 Annual Meeting of Shareholders, scheduled for June 18, 2026, to be held virtually. Key proposals for shareholder vote include the authorization for the Board to effect a reverse stock split with a ratio between 2:1 and 10:1, the election of one Class I director, and the ratification of Crowe LLP as the independent auditor. Shareholders will also cast an advisory vote on the 2025 compensation of Named Executive Officers. The company also detailed its outstanding $5.09 million in 8.0% Senior Secured Convertible Notes, with a conversion price of $1.05 per share and a maturity date extended to December 31, 2027.

DYADIC INTERNATIONAL INC filed an amendment to its Form 10-K to include previously omitted Part III information, detailing corporate governance, executive compensation, and director compensation for fiscal year 2025. The filing provides biographies of directors and executive officers, outlines compensation philosophy, and reports on outstanding equity awards. It also noted the retirement of two directors and a delinquent Section 16(a) report.